Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer

Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer

Abstract Overcoming resistance to therapy is a major challenge in castration-resistant prostate cancer (CRPC). Lineage plasticity towards a neuroendocrine phenotype enables CRPC to adapt and survive targeted therapies. However, the molecular mechanisms of epigenetic reprogramming during this process...

Full description

Bibliographic Details
Main Authors: Shankha S. Chatterjee, Juan F. Linares, Tania Cid-Diaz, Angeles Duran, Mohd. Imran K. Khan, Marta Osrodek, Nicholas J. Brady, Miguel Reina-Campos, Antonio Marzio, Varadha Balaji Venkadakrishnan, Martin K. Bakht, Francesca Khani, Juan Miguel Mosquera, Brian D. Robinson, Jenna Moyer, Olivier Elemento, Andrew C. Hsieh, David W. Goodrich, David S. Rickman, Himisha Beltran, Jorge Moscat, Maria T. Diaz-Meco
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-53874-2

Internet

https://doi.org/10.1038/s41467-024-53874-2

Similar Items